Ankylosing Spondylitis (AS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Ankylosing spondylitis (AS) is a type of arthritis primarily impacting the spine, potentially affecting other joints as well. It results in inflammation of the spinal vertebrae, leading to persistent and severe pain. In advanced stages, this inflammation can cause ankylosis, which is the formation of new bone in the spine, resulting in spine sections becoming fused and immobile. Additionally, AS can bring about inflammation, pain, and stiffness in various body parts, including the shoulders, hips, ribs, heels, and small joints of the hands and feet. On rare occasions, it can involve the eyes, known as iritis or uveitis, and affect the lungs and heart. A distinctive characteristic of ankylosing spondylitis is its impact on the sacroiliac (SI) joints, located at the spine’s base, where it connects with the pelvis. Although symptoms generally manifest in late adolescence or early adulthood, typically between the ages of 17 and 45, they can also emerge in childhood or later in life. Risk factors contributing to the development of AS encompass testing positive for the HLA-B27 marker, having a family history of the condition, and experiencing frequent gastrointestinal infections. Unlike other types of arthritis and rheumatic diseases, AS tends to affect younger individuals, usually those aged between 17 and 45. However, it can affect children and older individuals as well. The severity of AS varies significantly among individuals, with not everyone experiencing the most severe complications or spinal fusion. Some may endure occasional back pain and discomfort, while others may suffer from prolonged, severe pain and stiffness affecting various body parts. AS can be debilitating and, in some instances, result in disability. Although no known cure for AS exists, treatments and medications are available to alleviate symptoms and manage pain.
• It’s estimated that at least 1.7 million adults in the United States have AS, while 3.2 million have some form of axial spondyloarthritis.

Thelansis’s “Ankylosing Spondylitis (AS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Ankylosing Spondylitis (AS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Ankylosing Spondylitis (AS) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Ankylosing Spondylitis (AS) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Ankylosing Spondylitis (AS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033